–
Published on: 12/14/2020 13:19
Seqirus, a company completely dedicated to the research and production of flu vaccines, doubles the supply of enhanced flu vaccines for Italy. In times of Covid-19, the company “is committed to meeting the increase in demand linked to the provisions in force and the greater propensity to protect itself from the flu during the pandemic and is currently completing the delivery of the foreseen doses” , informs a company note.
“Despite the technical time required to produce the vaccine, the strong increase in demand globally and the delay in defining requests – continues the Seqirus press release – it was possible to quickly ensure a significant increase in the protection offer addressed to the population. elderly and fragile, in the logic of an international commitment but which sees Italy at the center. By December – the company assures – Seqirus will start to deliver all the doses reserved to the National Health Service “.
“A Swg survey, conducted at the beginning of the pandemic and published in ‘Vaccines’, showed a net increase in Italians planning to get vaccinated for the flu, equal to 49% in all age groups with the greatest impact on the elderly “, explains Maura Cambiaggi, CEO of Seqirus Italia.
“The good news is that this trend is consolidating. But beware – continues Cambiaggi – being able to respond to unexpected requests or requests far beyond expectations is not easy for a company that focuses on innovative vaccines, tailored according to age. and individual health conditions. This year, thanks to an unprecedented joint effort – he says – we have already been able to allocate doses in Italy since the beginning of October, in order to satisfy 95% of further requests. such a significant increase in demand from public health – he specifies – unfortunately we were not able to satisfy the demand on the pharmacy channel, and this is very sorry “.
This year, therefore – the note continues – over one in two elderly will be protected from the flu thanks to a Seqirus vaccine. And it is a positive fact given that, with increasing age, that immunosenescence process occurs which can require a stronger stimulus to increase the defenses and produce antibodies intended to block the infection in its bud or at least to reduce it. intensity and risk of complications. On the other hand, for some time now, following national and regional guidelines, the adjuvanted trivalent vaccine has been used in over 65 to support an increase in the immune response. The important thing is to protect yourself appropriately.
“The production of a vaccine, in terms of efficacy and safety, is one of the most complex processes in the panorama of the pharmaceutical industry, as evidenced by the fact that only a few companies operate in this sector. In our case – concludes Cambiaggi – thanks to research we have developed innovative vaccines, designed to support the needs of different types of patients. Our goal, therefore, is to be able to respond effectively to the needs of public health in Italy and in the world, for this reason it is essential to plan orders sufficiently in advance “.
–
REPRODUCTION RESERVED © Copyright Adnkronos.
